drugset / Trial / NCT01882504
Proof of Concept Study of Gevokizumab in the Treatment of Pyoderma Gangrenosum
NaSingle-groupOpen-labelTreatment
Summary
The study will evaluate the safety and biologic activity of gevokizumab in subjects in the acute inflammatory phase of pyoderma gangrenosum.
Timeline
- Start
- 2013-05
- Primary completion
- 2015-10
- Completion
- 2015-10
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | gevokizumab | Monoclonal antibody | — | Subcutaneous |